Cardiorenal versus renocardiac syndrome: is there a difference?

Robert W Schrier

doi:10.1038/ncpneph0673 | Full Text | PDF (120K)

Does correction of anemia slow the progression of chronic kidney disease?

Ajay K Singh

Since the publication of the CHOIR and CREATE study results, tremendous attention has focused on the cardiovascular effects of anemia correction in patients with chronic kidney disease. Less publicized has been the finding of a potentially higher risk of progression to end-stage renal disease among patients assigned to a higher hemoglobin target. Ajay K Singh examines whether the sum of evidence indicates a harmful or a beneficial effect of anemia correction on the progression of kidney disease.

doi:10.1038/ncpneph0637 | Full Text | PDF (163K)

A diagnostic and treatment algorithm for dense deposit disease

doi:10.1038/ncpneph0645 | Full Text | PDF (100K)

Frequent nocturnal hemodialysis improves outcomes compared with conventional hemodialysis

doi:10.1038/ncpneph0647 | Full Text | PDF (110K)

KDOQI update of hemoglobin target

doi:10.1038/ncpneph0649 | Full Text | PDF (100K)

Measuring hemodialysis vascular access flow by the temperature gradient method

doi:10.1038/ncpneph0629 | Full Text | PDF (101K)

No apparent benefits of IDPN over oral supplements in malnourished hemodialysis patients

doi:10.1038/ncpneph0644 | Full Text | PDF (113K)

Homocysteine lowering does not improve survival in advanced CKD or ESRD

doi:10.1038/ncpneph0630 | Full Text | PDF (112K)

Mortality in hemodialysis patients treated with sevelamer or calcium-based phosphate binders

doi:10.1038/ncpneph0652 | Full Text | PDF (102K)

Prophylactic hemodialysis prevents renal deterioration after coronary angiography

doi:10.1038/ncpneph0643 | Full Text | PDF (101K)

Anti-MICA antibodies might contribute to kidney allograft loss

doi:10.1038/ncpneph0651 | Full Text | PDF (101K)

Comparing the Cockcroft–Gault and MDRD equations for calculation of GFR and drug doses in the elderly

Nathaniel Berman and Thomas H Hostetter

doi:10.1038/ncpneph0627 | Full Text | PDF (162K)

Lead chelation therapy retards the decline of renal function in patients with chronic kidney disease

Vecihi Batuman

doi:10.1038/ncpneph0617 | Full Text | PDF (164K)

Utility of the buttonhole cannulation method for hemodialysis patients with arteriovenous fistulas

Zbylut J Twardowski

doi:10.1038/ncpneph0641 | Full Text | PDF (163K)

Can plasma cystatin C level be used to estimate residual renal function in patients on dialysis?

Olof Heimbürger

doi:10.1038/ncpneph0621 | Full Text | PDF (165K)

Dual transplantation of kidneys from expanded criteria donors: maximizing the use of a scarce resource

Manikkam Suthanthiran

doi:10.1038/ncpneph0628 | Full Text | PDF (167K)

Renal disease in patients with cancer

Kevin W Finkel and John R Foringer

There are several renal syndromes that are unique to patients with cancer, being caused either by the cancer itself or by its treatment. This Review provides nephrologists—who are essential members of the multidisciplinary team that cares for patients with malignancy—with an overview of these syndromes. The article is divided into sections that deal with the renal impact of different cancer types, interventions, and commonly used chemotherapeutic and biological agents.

doi:10.1038/ncpneph0622 | Full Text | PDF (368K)

Does hemolytic uremic syndrome differ from thrombotic thrombocytopenic purpura?

Fadi Fakhouri and Véronique Frémeaux-Bacchi

The difficulties that are inherent in the differential diagnosis of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura are a function of the overlap in presenting features. The authors of this Review assert that patient management could be more usefully directed by basing diagnosis on recently elucidated pathogenic mechanisms. To that end, they discuss the involvement of deficiencies in metalloprotease ADAMTS13, and dysfunctional complement proteins.

doi:10.1038/ncpneph0670 | Full Text | PDF (512K)